These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 25216371)

  • 21. The influence of the HPG axis on stress response and depressive-like behaviour in a transgenic mouse model of Huntington's disease.
    Du X; Pang TY; Mo C; Renoir T; Wright DJ; Hannan AJ
    Exp Neurol; 2015 Jan; 263():63-71. PubMed ID: 25246229
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pridopidine for the treatment of Huntington's disease.
    Shannon KM
    Expert Opin Investig Drugs; 2016; 25(4):485-92. PubMed ID: 26881734
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current therapeutic advances in patients and experimental models of Huntington's disease.
    Brett AC; Rosenstock TR; Rego AC
    Curr Drug Targets; 2014 Mar; 15(3):313-34. PubMed ID: 24266585
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biomarkers for Huntington's disease.
    Wild EJ; Tabrizi SJ
    Expert Opin Med Diagn; 2008 Jan; 2(1):47-62. PubMed ID: 23485116
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Grasping premanifest Huntington's disease - shaping new endpoints for new trials.
    Reilmann R; Bohlen S; Klopstock T; Bender A; Weindl A; Saemann P; Auer DP; Ringelstein EB; Lange HW
    Mov Disord; 2010 Dec; 25(16):2858-62. PubMed ID: 20818671
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnostic criteria for Huntington's disease based on natural history.
    Reilmann R; Leavitt BR; Ross CA
    Mov Disord; 2014 Sep; 29(11):1335-41. PubMed ID: 25164527
    [TBL] [Abstract][Full Text] [Related]  

  • 27. GPi-DBS in Huntington's disease: results on motor function and cognition in a 72-year-old case.
    Fasano A; Mazzone P; Piano C; Quaranta D; Soleti F; Bentivoglio AR
    Mov Disord; 2008 Jul; 23(9):1289-92. PubMed ID: 18512756
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic options for Huntington's disease.
    Grimbergen YA; Roos RA
    Curr Opin Investig Drugs; 2003 Jan; 4(1):51-4. PubMed ID: 12625029
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cell therapy in Huntington's disease: Taking stock of past studies to move the field forward.
    Bachoud-Lévi AC; Massart R; Rosser A
    Stem Cells; 2021 Feb; 39(2):144-155. PubMed ID: 33176057
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emerging drug therapies in Huntington's disease.
    Mason SL; Barker RA
    Expert Opin Emerg Drugs; 2009 Jun; 14(2):273-97. PubMed ID: 19453283
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New Avenues for the Treatment of Huntington's Disease.
    Kim A; Lalonde K; Truesdell A; Gomes Welter P; Brocardo PS; Rosenstock TR; Gil-Mohapel J
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445070
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Experimental models of Huntington's disease].
    García-Ramos R; del Val-Fernández J; Catalán-Alonso MJ; Barcia-Albacar JA; Matías-Guiu J
    Rev Neurol; 2007 Oct 1-15; 45(7):437-41. PubMed ID: 17918112
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biomarkers in Alzheimer's disease drug development.
    Cummings JL
    Alzheimers Dement; 2011 May; 7(3):e13-44. PubMed ID: 21550318
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Animal models of Huntington's disease for translation to the clinic: best practices.
    Menalled L; Brunner D
    Mov Disord; 2014 Sep; 29(11):1375-90. PubMed ID: 25216369
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The fate of cell grafts for the treatment of Huntington's disease: the post-mortem evidence.
    Cisbani G; Cicchetti F
    Neuropathol Appl Neurobiol; 2014 Feb; 40(1):71-90. PubMed ID: 24304236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. From open to large-scale randomized cell transplantation trials in Huntington's disease: Lessons from the multicentric intracerebral grafting in Huntington's disease trial (MIG-HD) and previous pilot studies.
    Bachoud-Lévi AC
    Prog Brain Res; 2017; 230():227-261. PubMed ID: 28552231
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic advances in Huntington's Disease.
    Shannon KM; Fraint A
    Mov Disord; 2015 Sep; 30(11):1539-46. PubMed ID: 26226924
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytotoxicity models of Huntington's disease and relevance of hormetic mechanisms: A critical assessment of experimental approaches and strategies.
    Calabrese EJ; Bhatia TN; Calabrese V; Dhawan G; Giordano J; Hanekamp YN; Kapoor R; Kozumbo WJ; Leak RK
    Pharmacol Res; 2019 Dec; 150():104371. PubMed ID: 31415915
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Supporting Huntington's Disease Families Through the Ups and Downs of Clinical Trials.
    Andrew KM; Fox LM
    J Huntingtons Dis; 2023; 12(1):71-76. PubMed ID: 37038822
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Addressing the Value of Multidisciplinary Clinical Care in Huntington's Disease: A Snapshot of a New Huntington's Disease Center.
    Bardakjian TM; Klapper J; Carey A; Wood J; Pauly M; Gasper K; Lawler K; Tran B; Bell Y; Zwil A; Gonzalez-Alegre P
    J Huntingtons Dis; 2019; 8(4):501-507. PubMed ID: 31381522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.